Sotorasib Tablets Market Report 2026

Sotorasib Tablets Market Overview

• Sotorasib Tablets market size has reached to $1.92 billion in 2025 • Expected to grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Rising Prevalence Of Cancer Fueling The Market Growth Due To Increasing Life Expectancy • Market Trend: Combination Therapies Show Promise In Extending Progression-Free Survival In Advanced Cancers • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sotorasib Tablets Market?

Sotorasib tablets are a prescription medicine developed for the treatment of certain cases of non-small cell lung cancer in patients whose tumors carry the KRAS G12C gene mutation. The medicine works by binding to the abnormal KRAS protein, preventing it from sending signals that drive the uncontrolled growth and survival of cancer cells. This targeted inhibition can reduce tumor activity, slow disease progression, and improve treatment outcomes in patients who have limited options with standard therapies. The main dosage forms of sotorasib tablets are 40 milligrams (mg), 120 milligrams (mg), 240 milligrams (mg), and other dosage forms. The 40 mg tablets are a lower-strength form of the KRAS G12C inhibitor Lumakras, enabling precise dose adjustments for improved safety and tolerability. Sotorasib is used in patient populations including adolescents, adults, and senior adults. It is distributed through various channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels, and is used for applications including non-small cell lung cancer, colorectal cancer, and other indications. The end-users include hospitals, oncology centers, clinics, and other healthcare providers.

What Is The Sotorasib Tablets Market Growth Forecast?

The sotorasib tablets market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing development of next-generation kras inhibitors, rising combination therapy approaches, expansion of targeted treatments into additional cancer indications, growing use of real-world evidence studies, increasing oncology precision medicine adoption. Major trends in the forecast period include increasing adoption of kras g12c inhibitor therapies, rising focus on targeted lung cancer treatments, growing use of oral oncology medications, expansion of companion diagnostic testing, enhanced monitoring of resistance mechanisms.

Global Sotorasib Tablets Market Segmentation

1) By Dosage Form: 40 Milligrams (Mg) Tablets, 120 Milligrams (Mg) Tablets, 240 Milligrams (Mg) Tablets, Other Dosage Forms 2) By Patient Demographics: Adolescents, Adult, Senior Adults 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 4) By Application: Non-Small Cell Lung Cancer, Colorectal Cancer, Other Applications 5) By End-User: Hospitals, Oncology Centers, Clinics, Other End-Users

What Are The Drivers Of The Sotorasib Tablets Market?

The rising prevalence of cancer is expected to propel the growth of the sotorasib tablets market going forward. Cancer is a group of diseases where abnormal cells grow uncontrollably, invade tissues, and can spread to other parts of the body. The increasing cancer prevalence is due to aging population, as advanced age is the most significant risk factor for developing most types of cancer, with the majority of cases occurring in individuals over 65 years old. Sotorasib tablets work by selectively and irreversibly targeting the KRAS G12C mutation, permanently locking the mutated protein in the off position to prevent uncontrolled cell growth in patients with advanced solid tumors, particularly non-small cell lung cancer. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the sotorasib tablets industry. The rising geriatric population is expected to propel the growth of the sotorasib tablets market going forward. The geriatric population refers to the group of older adults, typically aged 65 years and above, who may experience age-related physiological, psychological, and social changes. The rising geriatric population is primarily due to increased life expectancy, as advancements in healthcare, nutrition, and living conditions allow more people to live longer, resulting in a higher proportion of older adults in the population. Sotorasib tablets help the geriatric population by targeting KRAS G12C-mutated cancers, offering a precision therapy that addresses age-related vulnerabilities and improves treatment outcomes in older adults. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the rising geriatric population is driving the growth of the sotorasib tablets industry.

Key Players In The Global Sotorasib Tablets Market

Major companies operating in the sotorasib tablets market are Amgen Inc.

Global Sotorasib Tablets Market Trends and Insights

Major companies operating in the sotorasib tablets market are focusing on developing innovative therapies such as combination treatments to improve efficacy and overcome resistance. Combination treatments refer to using two or more drugs together to target cancer through multiple mechanisms simultaneously, helping to increase treatment effectiveness, overcome or delay drug resistance, reduce the likelihood of cancer recurrence, and improve overall patient outcomes and quality of life. For instance, in January 2025, Amgen Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C–mutated metastatic colorectal cancer (mCRC) who had previously received standard chemotherapy. This approval was based on the results of the Phase 3 CodeBreaK 300 study, which demonstrated that the combination more than doubled progression-free survival compared to the investigator’s choice of standard-of-care therapy, providing a significant new option for patients with this difficult-to-treat cancer. Sotorasib is a first-in-class, oral KRAS G12C inhibitor that works by selectively targeting and locking the mutant KRAS protein in its inactive state, thereby blocking cancer cell growth and signaling pathways driven by this mutation.

Regional Insights

North America was the largest region in the sotorasib tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sotorasib Tablets Market?

The sotorasib tablets market consists of sales of lumakras, lumykras, and diagnostic companion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sotorasib Tablets Market Report 2026?

The sotorasib tablets market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sotorasib tablets industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.